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Abstract 
Background: Human chorionic gonadotropin (HCG), one of the initial embryonic signals, is 
probably a major regulator of the embryo-endometrial relationship. This study aims to assess the 
advantage of HCG supplementation during the secretory phase of hormonally prepared cycles for 
the transfer of cryopreserved-thawed embryos. 
Materials and Methods: This study was a randomized clinical trial. Infertile women who were 
candidates for frozen-thawed embryo transfers entered the study and were divided into two groups, 
HCG and control. The endometrial preparation method was similar in both groups: all women received 
estradiol valerate (6 mg) po per day from the second day of the menstrual cycle and progesterone 
in oil (100 mg) intramuscular (I.M.) when the endometrial thickness reached 8 mm. Estradiol and 
progesterone were continued until the tenth week of gestation. In the HCG group, patients received an 
HCG 5000 IU injection on the first day of progesterone administration and the day of embryo transfer.
Results: In this study, 130 couples participated: 65 in the HCG group and 65 in the control group. 
There was no statistically significant difference between groups regarding basic characteristics. 
Implantation rate, chemical pregnancy, clinical pregnancy, ongoing pregnancy, and abortion rates 
were similar in both groups.
Conclusion: Although HCG has some advantages in assisted reproductive technology (ART) 
cycles, our study did not show any benefit of HCG supplementation during the secretory phase of 
frozen cycles (Registration Number: IRCT201107266420N4). 
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Introduction
Implantation is a complex, important process (1). 
Embryo quality and uterine receptivity are important 
factors that influence the outcome of assisted repro-
ductive technology (ART). Various substances such 
as cyclic adenosine monophosphate (cAMP), relaxin, 
gonadotropin, prostaglandin E2 (PGE2), and glyco-
protein hormones that are secreted from the embryo 
or endometrium affect implantation (2-7). Secretion 
of human chorionic gonadotropin (HCG) is one of 
the initial embryonic signals. It is probably a major 
regulator of the embryo-endometrial relationship. 
Expression of the HCG/luteinizing hormone (HCG/
LH) receptor is observed in the endometrium during 
the secretory phase of menstrual cycles (7). HCG is 
usually defined as a key factor that can induce and 
develop in vitro decasualization of the endometrium 
(6, 8). HCG may have systemic and local effects on 
the embryo-endometrial microenvironment (9). 
Pregnancy rates following cryopreserved em-
bryo transfer cycles are usually lower than fresh 
embryo transfer cycles. However, transfer of ex-
cess embryos in frozen cycles increases the cumu-
lative pregnancy rates and decreases the costs. So 
an attempt to evaluate the factors that influence the 
success rate of cryopreserved cycles is important 
(9, 10). The aim of this study is to assess the ad-
vantage of HCG supplementation during the secre-
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tory phase of hormonally-prepared cycles for the 
transfer of cryopreserved-thawed embryos.
Materials and Methods
This randomized clinical trial was conducted at 
the Yazd Research and Clinical Center for Infertil-
ity, Shahid Sadoughi University of Medical Sciences 
between January 2009 and June 2011. The study was 
approved by the Ethics Committee of the university. 
Written informed consent was obtained from all 
couples. Women who had undergone in vitro ferti-
lization (IVF) or intracytoplasmic sperm injection 
(ICSI) with cryopreservation of excess embryos and 
fresh cycles with implantation failure entered the 
study. Women older than 38 years, those with a body 
mass index (BMI) >30 kg/m2, history of endocrine 
disorders, and severe endometriosis were excluded 
from the study. The patients were allocated into two 
groups: group 1 (HCG) and group 2 (control) as per-
formed by computerized randomization.
Morphological assessment of all embryos was 
performed on the second day after oocyte retrieval. 
We transferred two or three embryos. Any excess 
embryos that had less than 30% fragmentation were 
frozen by the vitrification method. After a two-step 
loading with equilibrant and vitrification solutions, 
embryos were loaded by a thin glass capillary on to 
the cryoton. After loading, nearly the entire solution 
was eliminated and only a fine layer covering the 
embryos remained. The embryos were flooded in to 
liquid nitrogen, a film part of cryoton was covered 
by a plastic cap, and we stored the sample in liq-
uid nitrogen. Thawing was performed at least two 
months after cryopreservation, when straws were 
exposed to air and then submerged in water. The 
cryoprotectant was eliminated using embryo-thaw-
ing media (Vitrolife). After thawing, the embryos 
were transferred to a culture media and evaluated 
24 hours later. We selected those embryos with less 
than 50% fragmentation for transfer.
The endometrial preparation process was similar 
in both groups. All women received oral estradiol 
valerate (2 mg, Aburaihan Co., Tehran, Iran) 6 mg 
per day from the second day of the menstrual cycle. 
Endometrial thickness was measured by vaginal ul-
trasonography. From the 13th day of the cycle when 
endometrial thickness reached 8 mm, intramuscu-
lar (IM) injections of progesterone in oil (100 mg; 
Aburaihan Co., Tehran, Iran) were administered to 
all subjects. Embryo transfer was performed three 
days after the beginning of progesterone adminis-
tration. Estradiol and progesterone were continued 
until the tenth week of gestational age.
In the HCG group, 5000 IU HCG (Pregnyl®, Or-
ganon, Oss, Netherlands) was injected on the first 
day of progesterone administration and on the day 
of embryo transfer. Embryo thawing was performed 
two days after the first progesterone injection. Em-
bryos were transferred one day after thawing by a 
Labotect catheter (Labotect, Gotting, Germany).
Chemical pregnancy was defined by serum β hCG 
>50 IU/L 12 days after embryo transfer and clinical 
pregnancy was defined by observation of fetal heart 
activity two weeks after positive β hCG. We defined 
miscarriage as the loss of pregnancy before the 20th 
week of gestation and ongoing pregnancy as con-
tinuation of pregnancy after the 12th week of gesta-
tion. Implantation rate was defined as the numbers 
of gestational sacs per 100 embryos transferred.
Statistical analysis
Statistical analysis was carried out using the sta-
tistical package for the social sciences (SPSS ver-
sion 15.0 for Windows, Chicago, IL). Both t test 
and chi-square test were used to detect significant 
differences between two groups. The level of sig-
nificance was set at p value<0.05.
Results
In this study, a total of 130 couples participated: 
65 in group 1 (HCG group) and 65 in group 2 (con-
trol group). The demographic and basic character-
istics of patients are shown in table 1. 
There were no statistically significant differences 
between groups regarding age (p=0.549), duration 
of infertility (p=0.368), basal follicle stimulating 
hormone (p=0.135), BMI (p=0.661), and etiology 
of infertility (p=0.201). The cycle characteristics 
and outcome of vitrification are shown in table 2. 
There were no statistically significant differences 
between groups regarding the numbers of thawed em-
bryos, numbers of transferred embryos, survival rates 
of thawing embryos and duration of freezing. Table 
3 shows the outcome of ART cycles. Implantation, 
chemical pregnancy, clinical pregnancy, ongoing preg-
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nancy, and abortion rates were similar in both groups.
Table 1: Basic patient characteristics in the two groups
Variables HCG group
Mean (SD)
Control group
Mean (SD)
P value
Age (Years) 28.47 ± 4.14 28.84 ± 3.71 0.549
Duration of infertil-
ity (Years)
6.58 ± 2.9 6.09 ± 2.74 0.368
Basal FSH (IU/L) 5.15 ± 1.66 5.60 ± 1.72 0.135
BMI (kg/m2) 23.67 ± 2.43 23.86 ± 2.3 0.661
Etiology of infertility 
Ovulatory , n (%) 13 (20) 13 (20) 0.201
Tubal, n (%) 9 (13.8) 10 (15.4)
Unexplained, n 
(%)
0 (0.0) 4 (3.1) 
Mixed, n (%) 42 (64.6) 35 (53.8)
Male, n (%) 1 (1.5) 4 (3.1)
Total, n (%) 63 (100) 65 (100)
Table 2: Cycle characteristics and outcome of vitrification
Variables HCG group
Mean (SD)
Control group
Mean (SD)
P value
Duration of freez-
ing (Months)
6.58 ± 3.1 6.09 ± 2.74 0.326
Number of thawed 
embryos
2.96 ± 0.17 2.89 ± 0.31 0.086
Survival rate after 
thawing (%)
91.79 ± 0.20 94.87 ± 0.12 0.299
Numbers of trans-
ferred embryos
2.73 ± 0.44 2.60 ± 0.49 0.095
Table 3: ART outcome in both groups
Variables HCG group Control group P Value
Implantation rate 
(%)
21.02 17.44 0.488
Chemical pregnancy 
rate, n (%)
27 (41.5) 25 (38.5) 0.429
Clinical pregnancy 
rate, n (%)
22 (30.8) 20 (30.8.7) 0.426
Ongoing pregnancy 
rate, n (%)
20 (30.8) 18 (27.7) 0.424
Miscarriage rate, 
n (%)
7 (25.9) 7 (28.0.4) 0.556
Endometrial thick-
ness (mm)
8.83±1.6 9.08±1.2 0.528
Discussion
While treatment protocols, early embryo development, 
and laboratory techniques have considerably improved 
over the last decades in ART cycles, little has been iden-
tified about the events that occur after the transfer of em-
bryos in to the uterine cavity. About 75% of embryos do 
not implant after transfer. Thus, to improve implantation 
rates we need additional understanding of the molecular 
mechanisms governing the endometrial preparation for 
embryo implantation (11-13).
According to our data, for better embryo implanta-
tion it is necessary to have a good embryo with ap-
propriate morphology and developmental potential 
as well as a high concentration of HCG. In this study 
we have hypothesized that HCG supplementation in 
the secretory phase of the endometrium during the 
frozen embryo cycle may increase the implantation 
and eventually the pregnancy rate. However our find-
ings have contradicted with this hypothesis. 
Our study showed that HCG supplementation for 
endometrial preparation in cryopreserved cycles had 
no more benefit than estradiol and progesterone. 
Our finding was consistent with the Ben-Meir et al. 
study where the researchers observed that recom-
binant HCG supplementation during the secretory 
phase of the frozen-thawed embryo transfer cycles 
showed no advantage in terms of pregnancy and im-
plantation rates (9). Similar to our study, they did 
not use a GnRH agonist for down-regulation, and 
thus endogenous basal LH secretion was not com-
pletely suppressed. Tesarik et al. (14) demonstrated 
that HCG supplementation during the luteal phase 
of the oocyte donation cycle improved pregnancy 
rates only in cycles with low endogenous LH.
Mansour et al. (15) have shown that intrauterine 
injection of 500 IU HCG prior to embryo transfer 
significantly increased pregnancy rate after ART. 
They concluded that the HCG level positively cor-
related with the level of trophoblastic tolerance.
HCG plays a central role in controlling implantation 
and early embryonic development (16). This hormone 
is produced very early by the developing embryo and 
is secreted in relatively high concentrations. HCG may 
effectively regulate endometrial preparation via the 
following processes (17): i. local down-regulation of 
insulin growth factor binding protein 1 (IGF BP-1) 
by HCG leads to the prolongation of the window of 
endometrium; ii. HCG augments the endometrial re-
ceptivity by increasing angiogenesis through increased 
local vasoendothelial growth factor (VEGF) (18, 19); 
iii.HCG interacts with the production of galactosemic 
fibroblast (M-GSF) and leukemia inhibiting factor 
(LIF) that are important for implantation (20); iv. HCG 
significantly inhibits the production of metalloprotein-
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ase (21); and v. HCG has been demonstrated to have 
an impact on the trophoblasts, resulting in improved 
differentiation and invasion potential (7, 22).
Fatemi et al. have concluded that the spontaneous 
natural cycle is superior to the HCG induced natu-
ral cycle. They showed a negative effect of HCG 
administration on pregnancy. These researchers hy-
pothesized that the significantly lower pregnancy 
rate in the HCG group was related to desynchroniza-
tion between a receptive endometrium and embryo, 
which resulted from the endometrial effects of HCG. 
Administration of HCG has been shown to induce 
a series of events in the endometrium which begins 
several days later. These events may have a negative 
impact on implantation (23). Additional studies with 
larger sample sizes are required for better evaluation. 
Conclusion 
While HCG has some advantages in the ART cycle, 
our study did not show any advantage of HCG sup-
plementation in the secretory phase of frozen cycles. 
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